Fierce Pharma

APRIL 14, 2023

AACR: Patient deaths taint Roche's industry-first early-stage liver cancer readout for Tecentriq and Avastin aliu Fri, 04/14/2023 - 22:19

Patients 264

Patients 264

Fierce Pharma

MAY 16, 2023

BeiGene, Max Foundation team up to provide free Brukinsa to CLL patients in 29 low-income countries aliu Tue, 05/16/2023 - 15:35

Patients 263

Patients 263

Fierce Pharma

MARCH 6, 2023

ACC23: J&J's combo pill of Opsumit plus tadalafil improves blood flow in PAH patients kdunleavy Mon, 03/06/2023 - 08:29

Patients 246

Patients 246

Fierce Pharma

MARCH 6, 2023

ACC23: Bayer and J&J's Xarelto reduces ischemia risk for PAD patients after revascularization surgery kdunleavy Mon, 03/06/2023 - 07:09

Patients 246

Patients 246

Fierce Pharma

FEBRUARY 24, 2023

J&J wins EU backing for PARP combo Akeega in prostate cancer—but only in some patients aliu Fri, 02/24/2023 - 12:07

Patients 246

Patients 246

MedCity News

DECEMBER 2, 2022

Health system leaders believe that improving patient access should be their top priority when strategically planning for 2023, according to a new report from the KLAS Research and UPMC’s Center for Connected Medicine.

Patients 128

Patients Medicine 128

Fierce Pharma

SEPTEMBER 11, 2023

In a poster presented over the weekend at Psych Congress 2023, Qelbree was shown to sharpen the focus of children 6 and older when combined with a stimulant. The drug also showed efficacy in adult patients when used over a long period of time.

Medicine 299

Medicine Patients 299

Fierce Pharma

JUNE 28, 2023

With a spring approval in hand, Reata Pharmaceuticals has been waiting patiently to launch its first commercial product, Skyclarys. million sales target for 2023.

FDA 263

FDA Sales Pharmaceutical Patients 263

Fierce Pharma

APRIL 26, 2023

FDA argues AstraZeneca, Merck's Lynparza only works in subset of prostate cancer patients aliu Wed, 04/26/2023 - 14:19

FDA 147

FDA Patients 147

MedCity News

FEBRUARY 2, 2023

The percentage of respondents who know of a patient death being caused by nurses being assigned too many patients nearly doubled in the past seven years — from 22% in 2016 to 42% in 2023.

Patients 131

Patients Safety 131

European Pharmaceutical Review

JANUARY 29, 2024

N-Nitrosamines By far the biggest issue bedevilling industry during 2023 was the continuing N-nitrosamine contamination saga, which was covered in the third issue of EPR 2023. 4 The use of CPCA assessments allows for the assignment of scientifically justifiable higher acceptable intakes (AIs), without impacting patient safety.

Pharmaceutical 111

Pharmaceutical Food and Drug Administration Medicine FDA 111

Fierce Pharma

MARCH 27, 2023

Discussing the rise of patient-centricity in life sciences jpiatt Mon, 03/27/2023 - 14:49

Patients 130

Patients 130

Fierce Pharma

MARCH 2, 2023

Harnessing Data to Improve Patient Access And Optimize Gross-to-Net jpiatt Thu, 03/02/2023 - 14:47

Patients 130

Patients 130

pharmaphorum

NOVEMBER 6, 2023

UK patient data project reaches one million volunteers Phil.Taylor Mon, 06/11/2023 - 08:55 Bookmark this

Patients 119

Patients 119

pharmaphorum

OCTOBER 16, 2023

Bayer adds QR code to pack to help blind patients Phil.Taylor Mon, 16/10/2023 - 09:58 Bookmark this

Patients 122

Patients 122

MedCity News

MAY 7, 2023

To positively impact the health of the most significant number of people, dentistry must be amplified by AI and truly become preventive care.

Patients 115

Patients 115

European Pharmaceutical Review

OCTOBER 10, 2023

Patients were 1.21 percent of patients treated with the nasal spray formulation of esketamine reported a TEAE that resolved same day. percent of quetiapine XR patients. percent of esketamine nasal spray-treated patients who reported a TEAE that persisted for more than one day, versus 74.7 However, 82.6 There were 53.6

Safety 109

Safety Leads Patients Pharmaceutical 109

European Pharmaceutical Review

DECEMBER 11, 2023

Results from MaaT Pharma’s Early Access Program (EAP) for its microbiome-based therapy MaaT013, have demonstrated positive overall response and overall survival rates in European patients with graft-versus-host disease (GvHD). The findings were presented at the 2023 American Society of Hematology (ASH) Annual Meeting.

Patients 119

Patients Pharma Pharmaceutical 119

European Pharmaceutical Review

OCTOBER 23, 2023

An intravesical drug delivery system designed to provide sustained local release of gemcitabine into the bladder, has enabled 77 percent of bladder cancer patients (23 out of 30) to achieve a complete response (CR) in the Cohort 2 of the Phase IIb SunRISe-1 study. Sanofi-Janssen collaboration to advance novel E.

Pharmaceutical 111

Pharmaceutical Safety Patients Leads 111

European Pharmaceutical Review

MARCH 21, 2024

I joined Pfizer in January 2023 as a health access specialist, after working at Clalit Health Services in Israel for almost 20 years. What is patient centricity and why is it an important consideration in drug development? What are the three main factors to consider when looking to develop patient-centric drug products?

Healthcare 110

Healthcare Healthcare Patients Medicine 110

European Pharmaceutical Review

OCTOBER 25, 2023

CPHI Barcelona has announced the winners of 2023 CPHI Pharma Awards. A wearable patch that uses ultrasounds to deliver drugs subcutaneously, removes the need for needles and cannulas, creating a unique drug delivery system that ensures patient comfort.

Pharma 110

Pharma Manufacturing Management Pharmaceutical 110

Clarivate

SEPTEMBER 19, 2023

The Citation Laureates 2023 list has been announced, recognizing a select group of influential, highly cited researchers whose contributions are on par with Nobel Prize recipients. The impact on our world Citation Laureates 2023 have reshaped the boundaries of human knowledge, pushing the frontiers of what is known and what is possible.

Electronics 111

Electronics Medicine Government Patients 111

European Pharmaceutical Review

JUNE 30, 2023

The power of rapid methods for fungal ID By leveraging rapid identification techniques, pharmaceutical facilities can enhance their ability to detect and mitigate fungal contamination, safeguarding product quality and patient safety. The post In Depth Focus QA/QC Microbiology/RMM 2023 appeared first on European Pharmaceutical Review.

Safety 105

Safety Pharmaceutical Patients 105

pharmaphorum

NOVEMBER 24, 2023

International Health Partners' Christmas campaign: Working with pharma for patients worldwide Nicole.Raleigh Fri, 24/11/2023 - 11:24 Bookmark this

Pharma 110

Pharma Patients 110

European Pharmaceutical Review

OCTOBER 2, 2023

CPHI Barcelona, the renowned global pharma event, is set to take centre stage from 24 to 26 October 2023 at Fira Barcelona Gran Via, Spain. Credit: CPHI What’s new for 2023? Awarding Excellence The CPHI Pharma Awards will mark its 20th anniversary with a grand ceremony on 24 October 2023. CPHI Pharma Awards 2023 Categories 1.

Manufacturing 105

Manufacturing Pharma Engineering Networking 105

European Pharmaceutical Review

DECEMBER 18, 2023

At the beginning of this year, EPR reported on the potential blockbuster pharmaceutical drugs to watch in 2023. The year 2023 also brought much advancement in the Alzheimer’s space for the pharmaceutical industry. Since then, EPR has covered developments for several of the therapies highlighted in the report.

Manufacturing 98

Manufacturing Food and Drug Administration Medicine Pharmaceutical manufacturing 98

European Pharmaceutical Review

NOVEMBER 6, 2023

IZERVAY ( avacincaptad pegol intravitreal solution) induced a year-over-year reductions in the rate of geographic atrophy lesion growth in patients with geographic atrophy secondary to age-related macular degeneration (AMD) in a Phase III trial, Astellas Pharma has announced. Astellas to accelerate ocular disease treatments with $5.9

Food and Drug Administration 101

Food and Drug Administration Safety Food Patients 101

Pharmaceutical Technology

MAY 30, 2023

According to GlobalData’s Looking Ahead to 2023 – the Future of Pharma report, five drugs set for approval in 2023 are projected to attain blockbuster status or near-blockbuster status by 2028 with US company dominance. These drugs are set to make a combined $4.34bn in sales in 2028. Similarly, Almirall S.A.,

Sales 105

Sales Marketing Prescription Pharma 105

PM360

OCTOBER 3, 2023

Director US Marketing and Patient Engagement, argenx US, Inc. Akil Hunte, Director, Patient Empowerment, FILSPARI Marketing Team, Travere Therapeutics Ophthalmology/Optometry: Maaza Martin, Senior Director, Marketing, Tarsus Pharmaceuticals, Inc. Cardiology: Bradley A. Yavornitzki, Senior Product Manager, U.S.

Education 122

Education Marketing Media Pharmaceutical 122

European Pharmaceutical Review

DECEMBER 12, 2022

A thirteen-year-old patient with relapsed T-cell acute lymphoblastic leukaemia (T-ALL) has been the first to be treated with base-edited T-cells via CD7 Chimeric Antigen Receptor (CAR)-T cell therapy, which enabled them to achieve remission 28 days later. . Six months later, the patient is doing well and is recovering at home.

Patients 124

Patients Consulting Recruitment Engineering 124

PM360

MARCH 24, 2023

In 2022, SXSW was all NFTs and metaverse activations and events, and in 2023 they weren’t anywhere to be found. Their website states: “In the AnchoringVR scenario patients select or create visual expressions of that experience and fuel them with audio recordings of their insights,” explains [Enosis co-founder Agnieszka] Sekula.

Media 119

Media Engineering Healthcare Healthcare 119

European Pharmaceutical Review

OCTOBER 19, 2023

These findings presented at the 2023 European AIDS Conference (EACS 2023) were based on the ongoing Bictegravir Single Tablet Regimen (BICSTaR) study. First paediatric EC approval of HIV drug The post EACS 2023: Gilead shares real-world evidence for Biktarvy® appeared first on European Pharmaceutical Review.

Safety 104

Safety Physicians Food Medical 104

European Pharmaceutical Review

FEBRUARY 7, 2023

A wave of important legislative changes is anticipated in the EU in 2023 making this year one of the biggest for the EU regulatory landscape governing the life sciences industry in recent times. As a key priority action under the ACT EU initiative, EU regulators plan to establish a multi-stakeholder platform (MSP) in 2023.

Medical 117

Medical Government Marketing Medicine 117

European Pharmaceutical Review

FEBRUARY 28, 2024

The implementation of the EU’s Health Technology Assessment Regulation (HTAR) 1 will play a key role in shaping the patient access pathway for ATMPs such as cell and gene therapies. Currently, these therapies primarily target rare or ultra-rare diseases with small patient populations, which therefore limits clinical study sizes.

Patients 97

Patients Ethics Healthcare Healthcare 97

PM360

SEPTEMBER 7, 2023

The “Kama Sutra” for Parkinson’s patients. A card game designed to help hemophilia patients exercise. A virtual product launch for patients akin to an iPhone debut. All of these are examples of how companies are taking a little more unconventional approach to patient engagement. Marketing and Patient Engagement, argenx.

Patients 105

Patients Pharma Education Marketing 105

Fierce Pharma

JUNE 5, 2023

The PD-1/L1 inhibitor class of drugs has vastly improved care for many patients with cancer, but some meds in the class have posted trial failures lately.

Patients 162

Patients 162

European Pharmaceutical Review

OCTOBER 12, 2023

September 2023 saw a wave of new pharmaceutical manufacturing facility expansions and launches across Europe. Therefore, this investment is supporting the sector to better deliver the changing needs and preferences of patients. Meath opened last month. Comment below to share your thoughts or reach out to us on social media.

Pharmaceutical manufacturing 104

Pharmaceutical manufacturing Manufacturing Pharmaceutical Pharma 104